Negotiations with Pharmaceutical Companies Offer Reassuring Lip Service to Shareholders, Advocates Say
Los Angeles, California – Pharmaceutical companies are facing scrutiny over their responses to negotiations with the Centers for Medicare and Medicaid Services (CMS) regarding drug prices. AstraZeneca CEO Pascal Soriot described the initial offer as “relatively encouraging,” while Pfizer CFO David Denton downplayed the impact on investors, calling it “modest.” Advocates, however, view these statements as mere lip service to calm shareholders rather than a genuine commitment to lowering drug prices. Merith Basey, executive director …